Invention Grant
- Patent Title: TAF1 inhibitors for the therapy of cancer
-
Application No.: US16077913Application Date: 2017-02-15
-
Publication No.: US10702518B2Publication Date: 2020-07-07
- Inventor: Sara Sdelci , Stefan Kubicek
- Applicant: CeMM—Forschungszentrum für Molekulare Medizin GmbH
- Applicant Address: AT Vienna
- Assignee: CeMM—Forschungszentrum für Molekulare Medizin GmbH
- Current Assignee: CeMM—Forschungszentrum für Molekulare Medizin GmbH
- Current Assignee Address: AT Vienna
- Agency: Parker Highlander PLLC
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@6ca970eb
- International Application: PCT/EP2017/053403 WO 20170215
- International Announcement: WO2017/140728 WO 20170824
- Main IPC: A61K31/4725
- IPC: A61K31/4725 ; A61K31/5517 ; A61P35/00 ; C07D413/12 ; C07D217/26 ; C07D407/12 ; C07D401/12 ; A61K45/06 ; A61K31/44 ; A61K31/513 ; G01N33/50 ; G01N33/68 ; G01N33/574 ; A61K31/4433 ; A61K31/472 ; A61K31/22 ; A61K31/517
Abstract:
The present invention relates to lactam derivatives of formula (I) for use as medicaments as well as pharmaceutical compositions comprising these compounds, particularly for use as inhibitors of the bromodomain-containing protein TAF1 (i.e., transcription initiation factor TFIID subunit 1) and for use in the treatment or prevention of cancer.
Public/Granted literature
- US20190117641A1 TAF1 INHIBITORS FOR THE THERAPY OF CANCER Public/Granted day:2019-04-25
Information query
IPC分类:
